Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884674 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21191796 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL21191600 | 0.98 | CNR2 (0.38) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19738702 | 0.97 | CNR2 (0.37) | CNR2CNR1TDP1L3MBTL1ESR1 | |
| SCHEMBL18869370 | 0.97 | CNR2 (0.37) | CNR2CNR1TDP1L3MBTL1ESR1 | |
| SCHEMBL19738148 | 0.95 | ESR1 (0.35) | CNR2CNR1TDP1L3MBTL1ESR1 | |
| SCHEMBL21718495 | 0.92 | CNR2 (0.36) | CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19738659 | 0.91 | ESR1 (0.33) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL19738625 | 0.88 | ESR1 (0.33) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL22023780 | 0.86 | CNR2 (0.45) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885TDP1 4189/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885TDP1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.